Therapeutic Vaccine Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Therapeutic Vaccine Market is Segmented by Products (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, and Other Products), Technology (Allogeneic Vaccine and Autologous Vaccine), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The report offers the value (in USD million) for the above segments.

Therapeutic Vaccine Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Therapeutic Vaccines Market Size

Therapeutic Vaccine Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 12.63 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Low

Major Players

Therapeutic Vaccine Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Therapeutic Vaccine Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Therapeutic Vaccines Market Analysis

The Therapeutic Vaccine Market is expected to register a CAGR of 12.63% during the forecast period.

While the sudden outbreak of the COVID-19 pandemic impacted most of the business sectors negatively, the therapeutic vaccine market showed significant growth in the years 2020 and 2021. The studied market is still booming with the detection of new COVID-19 variants. The increase in demand for the development of new vaccines to control the spread of the coronavirus disease has driven the studied market's growth. The demand for therapeutic vaccines increased during the pandemic, as did the investments from governments and business players across the world. For instance, in April 2021, Moderna and Samsung Biologics entered into a Manufacturing Services and Supply Agreement in which Samsung Biologics in South Korea will provide large-scale, commercial fill-finish manufacturing for the COVID-19 vaccine that Moderna intends to supply markets outside of the United States. Further, as per a press release by the United Nations International Children's Emergency Fund (UNICEF) in October 2021, a new ACT-Accelerator strategy was planned, which called for a USD 23.4 billion international investment to address disparities in the availability of COVID-19 diagnostics, vaccinations, and therapies worldwide. These investments during the pandemic were anticipated to impact the therapeutic vaccine development for COVID-19. As a result, the COVID-19 pandemic initially had a positive impact on the market; however, as the pandemic has subsided, the market has lost some traction; however, it is expected to grow steadily during the study's forecast period.

Factors such as the rise in research and development (R&D) expenditures by major players, soaring government funding for the development of vaccines, and the rising prevalence of various diseases are expected to fuel the growth of the market. For instance, in February 2021, the Indian government provided funds amounting to USD 365 million (INR 26.7 billion) to the Department of Health Research. This fund was provided to develop four new national virology institutes, nine new high-containment laboratories for studies on highly infectious pathogens, and one national institution. Such initiatives in developing countries are anticipated to drive market growth.

Furthermore, an increase in research and development (R&D) activities, collaborations, strategic partnerships, product approvals, and launches has generated market growth over the analysis period. For instance, in August 2022, researchers at the School of Pharmacy at Queen's University Belfast in Northern Ireland received funding from Breast Cancer Now to search for new treatments. The research team will be engaged in developing new treatments for an aggressive form of breast cancer. In this case, Niamh Buckley and Helen McCarthy from the School of Pharmacy secured a GBP 228,900 (USD 278,168) grant from Breast Cancer Now to tackle protein p53, found at very high levels in around 90% of triple-negative breast cancer tumors. Additionally, in August 2022, Merck (known as MSD outside the United States and Canada) and Orna Therapeutics, a biotechnology company, signed a collaboration agreement to discover, develop, and commercialize multiple programs, along with vaccines and therapeutics, in the areas of infectious disease and oncology. Orna will receive an upfront payment of USD 150 million from Merck under this collaboration agreement. Hence, these funds and investments are anticipated to generate demand for therapeutic vaccines as well. This is projected to fuel the market's growth.

Therefore, owing to the aforesaid factors, the studied market is anticipated to witness growth. However, strict legal requirements and frameworks and the high price associated with therapeutic vaccine development are likely to hinder the market's growth.

Therapeutic Vaccines Industry Overview

The therapeutic vaccine market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of international and local companies that hold market shares and are well-known, including AstraZeneca, Pfizer Inc., GSK plc., Merck & Co., Inc., Novartis AG, Phio Pharmaceuticals Corp., and INOVIO Pharmaceuticals, among others.

Therapeutic Vaccines Market Leaders

  1. Phio Pharmaceuticals Corp.

  2. GSK plc.

  3. Merck & Co., Inc.

  4. Pfizer Inc.

  5. Agenus Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Picture1.png
Need More Details on Market Players and Competiters?
Download PDF

Therapeutic Vaccines Market News

  • April 2022: A team at King's College London reportedly discovered the world's first cure for heart attacks using mRNA technology similar to the Covid vaccines.
  • March 2022: The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), launched a Phase 1 clinical trial evaluating three experimental HIV vaccines based on a messenger RNA (mRNA) platform. NIAID is sponsoring the study, called HVTN 302, and the NIAID-funded HIV Vaccine Trials Network (HVTN), based at Fred Hutchinson Cancer Research Center in Seattle, is conducting the trial.

Therapeutic Vaccines Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Diseases
    • 4.2.2 Favorable Government Funding For Vaccine Development
    • 4.2.3 Increase in R&D Expenditure by Major Market Players
  • 4.3 Market Restraints
    • 4.3.1 Huge Capital Expenditures Associated with Vaccine Development
    • 4.3.2 Stringent Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Products
    • 5.1.1 Autoimmune Disease Vaccines
    • 5.1.2 Neurological Disease Vaccines
    • 5.1.3 Cancer Vaccines
    • 5.1.4 Infectious Disease Vaccines
    • 5.1.5 Other Products
  • 5.2 By Technology
    • 5.2.1 Allogeneic Vaccine
    • 5.2.2 Autologous Vaccine
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agenus Inc.
    • 6.1.2 Argos Therapeutic Inc.
    • 6.1.3 Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
    • 6.1.4 Dendreon Corp (Sanpower Group Co., Ltd.)
    • 6.1.5 GlaxoSmithKline plc
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Novartis AG
    • 6.1.8 Pfizer, Inc.
    • 6.1.9 Phio Pharmaceuticals Corp.
    • 6.1.10 INOVIO Pharmaceuticals
    • 6.1.11 AstraZeneca
    • 6.1.12 BioNTech SE
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Therapeutic Vaccines Industry Segmentation

As per the scope of the report, a therapeutic vaccine is applied after an infection or disease occurs in order to induce antiviral immunity and alter the course of the disease. Therapeutic vaccines are used to cure diseases because, rather than immunizing for future disease protection, they work with the patient's own immune system to fight infection. The therapeutic vaccine market is segmented by products (autoimmune disease vaccines, neurological disease vaccines, cancer vaccines, infectious disease vaccines, and other products), technology (allogeneic vaccines and autologous vaccines), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Products Autoimmune Disease Vaccines
Neurological Disease Vaccines
Cancer Vaccines
Infectious Disease Vaccines
Other Products
By Technology Allogeneic Vaccine
Autologous Vaccine
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Therapeutic Vaccines Market Research FAQs

What is the current Therapeutic Vaccine Market size?

The Therapeutic Vaccine Market is projected to register a CAGR of 12.63% during the forecast period (2025-2030)

Who are the key players in Therapeutic Vaccine Market?

Phio Pharmaceuticals Corp., GSK plc., Merck & Co., Inc., Pfizer Inc. and Agenus Inc. are the major companies operating in the Therapeutic Vaccine Market.

Which is the fastest growing region in Therapeutic Vaccine Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Therapeutic Vaccine Market?

In 2025, the North America accounts for the largest market share in Therapeutic Vaccine Market.

What years does this Therapeutic Vaccine Market cover?

The report covers the Therapeutic Vaccine Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Therapeutic Vaccine Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Therapeutic Vaccine Industry Report

Statistics for the 2025 Therapeutic Vaccine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Therapeutic Vaccine analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.